Article
Oncology
Lakshmi Yarlagadda, Sravani Gundarlapalli, Richa Parikh, Reid D. Landes, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel A. Mitma, Clyde Bailey, Kerri M. Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee, Guido Tricot, Carolina Schinke
Summary: Multiple Myeloma (MM) is a common cancer of the bone marrow that remains incurable despite advancements in therapy. While Daratumumab has improved survival rates, heavily pretreated patients who progress on this treatment have poor clinical outcomes. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be a viable treatment option for selected patients who are refractory to Daratumumab.
Article
Immunology
Simone A. Minnie, Geoffrey R. Hill
Summary: The incidence of multiple myeloma is increasing globally, with substantial morbidity and mortality and remains largely incurable. Autologous stem cell transplantation (ASCT) has been shown to provide a progression free survival benefit in eligible patients beyond novel therapies. ASCT results in immune effects beyond cytoreduction, highlighting the potential for new immunotherapy maintenance strategies to prevent myeloma progression.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Anna Waszczuk-Gajda, Olaf Penack, Giulia Sbianchi, Linda Koster, Didier Blaise, Peter Remenyi, Nigel Russell, Per Ljungman, Marek Trneny, Jiri Mayer, Simona Iacobelli, Guido Kobbe, Christof Scheid, Jane Apperley, Cyrille Touzeau, Stig Lenhoff, Esa Jantunen, Achilles Anagnostopoulos, Laura Paris, Paul Browne, Catherine Thieblemont, Nicolaas Schaap, Jorge Sierra, Ibrahim Yakoub-Agha, Laurent Garderet, Jan Styczynski, Helene Schoemans, Ivan Moiseev, Rafael F. Duarte, Zinaida Peric, Silvia Montoto, Anja van Biezen, Malgorzata Mikulska, Mahmoud Aljurf, Tapani Ruutu, Nicolaus Kroeger, Curly Morris, Christian Koenecke, Stefan Schoenland, Grzegorz W. Basak
Summary: This post hoc analysis evaluated the rate of infectious and non-infectious complications after ASCT in multiple myeloma patients. The analysis included 3552 patients and found that complication rates decreased over time. Bacterial infections and gastrointestinal complications were the most common early events. The occurrence of complications was not associated with overall survival.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Hematology
Tan-Huy Chu, Sung-Hoon Jung, Kihyun Kim, Jae Hoon Lee, Yeung-Chul Mun, Soo-Mee Bang, Dok Hyun Yoon, Ho Sup Lee, Chang-Ki Min, Je-Jung Lee
Summary: Plasmacytoma was frequently developed at MM relapse after upfront ASCT in patients with plasmacytoma at the time of diagnosis, and plasmacytoma at relapse was significantly associated with a poor prognosis.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Chuanying Geng, Huixing Zhou, Huijuan Wang, Yanchen Li, Yun Leng, Zhiyao Zhang, Yuan Jian, Guangzhong Yang, Wenming Chen
Summary: This study found that ASCT may improve the overall survival (OS) and progression-free survival (PFS) of CD56 positive patients, while not impacting the survival of CD56 negative patients.
Article
Hematology
Jingyu Xu, Wenqiang Yan, Huishou Fan, Jiahui Liu, Lingna Li, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Lugui Qiu, Gang An
Summary: Autologous stem cell transplantation (ASCT) is the standard therapy for transplant-eligible multiple myeloma (TEMM) patients. The impact of residual tumor cells in the stem cell collection (SCC) on survival remains unclear. Our study found that detectable minimal residual disease (MRD) in SCC does not significantly predict inferior response or shorter survival after ASCT.
ANNALS OF HEMATOLOGY
(2023)
Article
Immunology
Rui Zhao, Jing Zhao, Yichuan Song, Wenxuan Fu, Qingtao Wang, Rui Zhang
Summary: This study aimed to find laboratory indicators that could predict disease progression in newly diagnosed multiple myeloma patients who underwent autologous stem cell transplantation (ASCT). The results showed that certain inflammation-related indicators, such as ANC, NLR, SIRI, and LMR, can serve as potential biomarkers for predicting the progression-free survival (PFS) of these patients.
JOURNAL OF INFLAMMATION RESEARCH
(2023)
Article
Oncology
Aina Oliver-Caldes, Juan Carlos Soler-Perromat, Ester Lozano, David Moreno, Alex Bataller, Pablo Mozas, Marta Garrote, Xavier Setoain, Juan Ignacio Arostegui, Jordi Yague, Natalia Tovar, Raquel Jimenez, Luis Gerardo Rodriguez-Lobato, M. Teresa Cibeira, Laura Rosinol, Joan Blade, Manel Juan, Carlos Fernandez de Larrea
Summary: This study retrospectively evaluated clinical and laboratory data of multiple myeloma patients who underwent induction treatment and autologous stem cell transplantation (ASCT). The study found that certain characteristics, such as younger age, female gender, lower clinical stage, and lower levels of certain biomarkers, were associated with sustained response for 5 or more years after ASCT. The depth of response achieved after induction and ASCT, as well as the maintenance treatment regimen, may impact progression-free survival.
FRONTIERS IN ONCOLOGY
(2022)
Review
Cell Biology
Sonia More, Laura Corvatta, Valentina Maria Manieri, Francesco Saraceni, Ilaria Scortechini, Giorgia Mancini, Alessandro Fiorentini, Attilio Olivieri, Massimo Offidani
Summary: The introduction of high-dose therapy and the development of new drugs have significantly improved the outcome of ASCT in MM patients. Incorporating second-generation proteasome inhibitors and monoclonal antibodies into treatment has greatly enhanced the efficacy of ASCT. The use of MRD assessment techniques has opened up the possibility of MRD-based response-adjusted trials.
Article
Oncology
Nina Rosa Neuendorff, Boryana Boshikova, Lutz Frankenstein, Marietta Kirchner, Christian Rohde, Hartmut Goldschmidt, Norbert Frey, Carsten Mueller-Tidow, Karin Jordan, Sandra Sauer, Maike Janssen
Summary: This study assessed the risk of bleeding with antiplatelet therapy (APT) during chemotherapy-induced thrombocytopenia in multiple myeloma patients. The results showed a slightly higher risk of bleeding in the ASA group, but it can still be considered safe to continue ASA during thrombocytopenia with a platelet count of 20-50/nl.
FRONTIERS IN ONCOLOGY
(2023)
Review
Medicine, General & Internal
Juan Liang, Ying Yang, Peijie He, Oscar Onayi Mandizadza, Wanjun Zhang, Shengyun Lin, Conghua Ji
Summary: This study systematically summarized the quality and evidence of multiple meta-analyses on the treatment of MM, including autologous stem cell transplantation. The findings revealed that the included meta-analyses were affected by possible bias and lacked protocol and registration. The methodological quality of the meta-analyses ranged from very low to moderate, and most outcome indicators were of low quality.
Article
Immunology
Ane Orrantia, Inigo Terren, Gabirel Astarloa-Pando, Carmen Gonzalez, Alasne Uranga, Juan J. Mateos-Mazon, Juan C. Garcia-Ruiz, Marta Rinon, Mercedes Rey, Silvia Perez-Fernandez, Olatz Zenarruzabeitia, Francisco Borrego
Summary: AutoHSCT in MM patients leads to significant changes in NK cell subsets and phenotype, with patients showing lower frequencies of the mature NKG2A-CD57+ NK cell subset experiencing better clinical outcomes. This suggests that the degree of NK cell maturation post-autoHSCT affects the disease progression and treatment outcomes in MM patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Yingying Zhai, Lingzhi Yan, Song Jin, Shuang Yan, Weiqin Yao, Jingjing Shang, Xiaolan Shi, Ruju Wang, Huizhu Kang, Jing Lu, Ziling Zhu, Fang Tang, Feng Wei, Chengcheng Fu, Depei Wu
Summary: In this retrospective study of 34 consecutively transplanted MM patients with renal impairment, adverse events occurred frequently but were manageable. ASCT not only deepened anti-myeloma efficacy but also slightly ameliorated renal function.
ANNALS OF HEMATOLOGY
(2023)
Article
Immunology
Egor Batorov, Tatiana A. Aristova, Natalia Pronkina, Vera V. Sergeevicheva, Svetlana A. Sizikova, Galina Y. Ushakova, Ekaterina Y. Shevela, Alexander A. Ostanin, Elena R. Chernykh
Summary: Homeostatic proliferation plays apparently a key role in the upregulation of PD-1 and TIM-3 on functional T cells after AHSCT and appears to be a normal physiological process, contrary to relapse-associated increase in PD-1+ and TIM-3+ T cells.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Oncology
Huixing Zhou, Yuan Jian, Juan Du, Junru Liu, Zhiyao Zhang, Guangzhong Yang, Guorong Wang, Ying Tian, Yanchen Li, Yin Wu, Wenming Chen, Weijun Fu, Juan Li, Wen Gao
Summary: This study aimed to establish a predictive nomogram for early relapse after autologous stem cell transplantation in multiple myeloma patients. The nomogram showed higher accuracy compared to other staging systems, suggesting its potential for modifying post-ASCT strategies for high-risk patients.
Article
Hematology
Shannon R. McCurdy, Stephen T. Muth, Hua-Ling Tsai, Heather J. Symons, Carol Ann Huff, William H. Matsui, Ivan Borrello, Douglas E. Gladstone, Lode J. Swinnen, Kenneth R. Cooke, Robert A. Brodsky, Javier Bolanos-Meade, Richard F. Ambinder, Ravi Varadhan, Leo Luznik, Richard J. Jones, Maria P. Bettinot, Ephraim J. Fuchs
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2018)
Article
Hematology
Jennifer A. Kanakry, Yvette L. Kasamon, Javier Bolanos-Meade, Ivan M. Borrello, Robert A. Brodsky, Ephraim J. Fuchs, Nilanjan Ghosh, Douglas E. Gladstone, Christopher D. Gocke, Carol Ann Huff, Christopher G. Kanakry, Leo Luznik, William Matsui, Huzefa J. Mogri, Lode J. Swinnen, Heather J. Symons, Richard J. Jones, Richard E. Anibinder
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2013)
Article
Hematology
Toshihiko Tanno, Yiting Lim, Qiuju Wang, Marta Chesi, P. Leif Bergsagel, Geoff Matthews, Ricky W. Johnstone, Nilanjan Ghosh, Ivan Borrello, Carol Ann Huff, William Matsui
Article
Oncology
Ravi K. Anchoori, Balasubramanyam Karanam, Shiwen Peng, Joshua W. Wang, Rosie Jiang, Toshihiko Tanno, Robert Z. Orlowski, William Matsui, Ming Zhao, Michelle A. Rudek, Chien-fu Hung, Xiang Chen, Kylie J. Walters, Richard B. S. Roden
Article
Oncology
Grace M. Wang, Hong Yuen Wong, Hiroyuki Konishi, Brian G. Blair, Abde M. Abukhdeir, John P. Gustin, D. Marc Rosen, Samuel Ray Denmeade, Zeshaan Rasheed, William Matsui, Joseph P. Garay, Morassa Mohseni, Michaela J. Higgins, Justin Cidado, Danijela Jelovac, Sarah Croessmann, Rory L. Cochran, Sivasundaram Karnan, Yuko Konishi, Akinobu Ota, Yoshitaka Hosokawa, Pedram Argani, Josh Lauring, Ben Ho Park
Article
Gastroenterology & Hepatology
Jennifer M. Bailey, Janivette Alsina, Zeshaan A. Rasheed, Florencia M. McAllister, Ya-Yuan Fu, Ruben Plentz, Hao Zhang, Pankaj J. Pasricha, Nabeel Bardeesy, William Matsui, Anirban Maitra, Steven D. Leach
Letter
Allergy
Jenny H. Lin, William Matsui, Charles Aloe, Roger D. Peng, Gregory B. Diette, Patrick N. Breysse, Elizabeth C. Matsui
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2013)
Article
Allergy
Corinne A. Keet, Wayne G. Shreffler, Roger D. Peng, William Matsui, Elizabeth C. Matsui
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2014)
Article
Medicine, Research & Experimental
Jung-Hyun Kim, Rajesh K. Thimmulappa, Vineet Kumar, Wanchang Cui, Sarvesh Kumar, Ponvijay Kombairaju, Hao Zhang, Joseph Margolick, William Matsui, Thomas Macvittie, Sanjay V. Malhotra, Shyam Biswal
JOURNAL OF CLINICAL INVESTIGATION
(2014)
Article
Oncology
Yvette L. Kasamon, Robert A. Brodsky, Michael J. Borowitz, Richard F. Ambinder, Pamela A. Crilley, Steve Y. Cho, Hua-ling Tsai, B. Douglas Smith, Douglas E. Gladstone, Hetty E. Carraway, Carol Ann Huff, William H. Matsui, Javier Bolanos-Meade, Richard J. Jones, Lode J. Swinnen
LEUKEMIA & LYMPHOMA
(2013)
Article
Oncology
Joshua F. Zeidner, Douglas E. Gladstone, Marianna Zahurak, William H. Matsui, Christopher Gocke, Richard J. Jones, B. Douglas Smith
Article
Oncology
Jasmin R. Agarwal, Qiuju Wang, Toshihiko Tanno, Zeshaan Rasheed, Akil Merchant, Nilanjan Ghosh, Ivan Borrello, Carol Ann Huff, Farhad Parhami, William Matsui
MOLECULAR CANCER THERAPEUTICS
(2014)
Review
Respiratory System
Muhammad Alamgeer, Craig D. Peacock, William Matsui, Vinod Ganju, D. Neil Watkins
Review
Oncology
Ajay Abraham, William Matsui
Summary: Myeloid malignancies arise from normal hematopoiesis and the Hedgehog (HH) signaling pathway plays an important role in these diseases, with SMO inhibitors approved for the treatment of acute myeloid leukemia (AML). Despite the broad activity of SMO inhibitors in AML, clinical studies in other myeloid malignancies remain inconclusive and further research is needed to explore their efficacy.
Article
Hematology
Nilanjan Ghosh, Xiaobu Ye, Hua-Ling Tsai, Javier Bolanos-Meade, Ephraim J. Fuchs, Leo Luznik, Lode J. Swinnen, Douglas E. Gladstone, Richard F. Ambinder, Ravi Varadhan, Satish Shanbhag, Robert A. Brodsky, Ivan M. Borrello, Richard J. Jones, William Matsui, Carol Ann Huff
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2017)
